Now on

Orphan Drug Designation for the use of Teicoplanin in Cystic Fibrosis

The European Commission grants Orphan Drug Designation to Neupharma for the use of Teicoplanin in Cystic Fibrosis, a program developed in collaboration with Rare Partners

RP announcement - read more
Rare Partners supports the Istituto Italiano di Tecnologia (IIT) for the development of an innovative artificial retina

Rare Partners supports the IIT for the development of an innovative artificial retina 

RP announcement - read more
A new Orphan Drug Designation to Sirolimus

A new Orphan Drug Designation to Sirolimus

RP announcement - read more
Rare Partners presents a poster on Thalassemia project

Rare Partners presents a poster on Thalassemia project.

RP announcement - read more
US Patent Office has issued a patent covering the use of trimethylangelicin in Cystic Fibrosis

The United States Patent and Trademark Office has issued on March 15th the US Patent number 9283206 covering the use of trimethylangelicin (TMA) as CFTR Corrector in Bronchial Epithelial Cells.

Press release - read more